-
Publication Venue For
-
Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores..
261:55-63.
2023
-
Postoperative pericardial effusion, pericardiotomy, and atrial fibrillation: An explanatory analysis of the PALACS trial..
260:113-123.
2023
-
Variation in resource utilization and mortality among patients with varying MR type and severity..
260:44-57.
2023
-
Generalizability of an EHR-Network Dataset to the United States for Cardiovascular Disease Conditions: Comparison of Cerner Real World Data with the National Inpatient Sample.
2023
-
Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study..
259:30-41.
2023
-
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa study..
262:75-82.
2023
-
Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial..
258:119-128.
2023
-
Public reporting of black participation in anti-hypertensive drug clinical trials..
258:129-139.
2023
-
Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction..
258:17-26.
2023
-
Trends in outcomes and resource utilization for acute myocardial infarction admissions during the COVID-19 pandemic..
258:114-118.
2023
-
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial..
257:120-129.
2023
-
Clinical and Cost Implications of Deferred Testing in Low-risk Patients with Stable Chest Pain: A Simulation Using the PROMISE Trial.
2023
-
Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design..
256:2-12.
2023
-
Physical activity and relationship to physical function, quality of life, and cognitive function in older patients with acute decompensated heart failure..
256:85-94.
2023
-
Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry..
254:102-111.
2022
-
Glycemic status and the association of change in blood pressure with incident cardiovascular disease..
254:48-56.
2022
-
ISCHEMIA-EXTEND studies: Rationale and design..
254:228-233.
2022
-
Identifying quality of life outcome patterns to inform treatment choices in ischemic cardiomyopathy..
254:12-22.
2022
-
Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF..
254:112-121.
2022
-
Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: Rationale and design of the STEMI-DTU randomized pivotal trial..
254:122-132.
2022
-
The pediatric heart network's study on long-term outcomes of children with HLHS and the impact of Norwood Shunt type in the single ventricle reconstruction trial cohort (SVRIII): Design and adaptations..
254:216-227.
2022
-
Corrigendum to "Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease" [Am Heart J (2021) 231:36-44]..
253:99-100.
2022
-
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial..
253:86-98.
2022
-
Associations of a polygenic risk score with coronary artery disease phenotypes in the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial..
252:12-15.
2022
-
National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey..
252:60-69.
2022
-
Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction-1-year follow-up results of the COMPARE CRUSH trial..
252:26-30.
2022
-
The trial to assess chelation therapy 2 (TACT2): Rationale and design..
252:1-11.
2022
-
Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model..
251:13-24.
2022
-
Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study..
251:127-136.
2022
-
Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial..
251:91-100.
2022
-
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial..
251:1-12.
2022
-
Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis..
251:101-114.
2022
-
Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial..
251:115-126.
2022
-
Comparison of severe maternal morbidity in pregnancy by modified World Health Organization Classification of maternal cardiovascular risk..
250:11-22.
2022
-
Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial..
249:86-97.
2022
-
Preexisting frailty and outcomes in older patients with acute myocardial infarction..
249:34-44.
2022
-
Randomized evaluation of vessel preparation with orbital atherectomy prior to drug-eluting stent implantation in severely calcified coronary artery lesions: Design and rationale of the ECLIPSE trial..
249:1-11.
2022
-
ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor..
249:76-85.
2022
-
Associated factors and clinical outcomes in mechanical circulatory support use in patients undergoing high risk on-pump cardiac surgery: Insights from the LEVO-CTS trial..
248:35-41.
2022
-
Independence of clinical events committees: A consensus statement from clinical research organizations..
248:120-129.
2022
-
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19..
247:76-89.
2022
-
Trends of blood pressure control in the U.S. during the COVID-19 pandemic..
247:15-23.
2022
-
Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines - heart failure participating centers..
246:1-11.
2022
-
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018..
246:93-104.
2022
-
Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction..
246:74-81.
2022
-
Rationale and design of a randomized trial evaluating an external support device for saphenous vein coronary grafts..
246:12-20.
2022
-
The influence of heart failure on clinical and economic outcomes among older adults ≥75 years of age with acute myocardial infarction..
246:65-73.
2022
-
Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry..
245:90-99.
2022
-
Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction..
245:110-116.
2022
-
Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study..
245:51-59.
2022
-
Dysglycemia and incident heart failure among blacks: The jackson heart study..
245:1-9.
2022
-
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study..
245:41-50.
2022
-
Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation..
245:29-40.
2022
-
Fibroblast growth factor-23 and subclinical markers of cardiac dysfunction: The coronary artery risk development in young adults (CARDIA) study..
245:10-18.
2022
-
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose..
245:19-28.
2022
-
The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial..
245:136-148.
2022
-
Tricuspid valve disease prevalence and the impact of tricuspid valve surgery on cardiovascular events and hospital resource use in medicare beneficiaries..
245:100-109.
2022
-
Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices..
244:116-124.
2022
-
Bimodal distribution of atrial fibrillation burden in 3 distinct cohorts: What is 'paroxysmal' atrial fibrillation?.
244:149-156.
2022
-
Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?.
244:135-148.
2022
-
Associations between neighborhood socioeconomic cluster and hypertension, diabetes, myocardial infarction, and coronary artery disease within a cohort of cardiac catheterization patients..
243:201-209.
2022
-
Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia..
243:187-200.
2022
-
The NHLBI Study on Long-terM OUtcomes after the Multisystem Inflammatory Syndrome In Children (MUSIC): Design and Objectives..
243:43-53.
2022
-
The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries..
243:110-121.
2022
-
Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018..
243:103-109.
2022
-
Cardiovascular risk and outcomes in symptomatic patients with suspected coronary artery disease and non coronary vascular disease: A report from the PROMISE trial..
242:82-91.
2021
-
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial..
242:115-122.
2021
-
Patient characteristics, care patterns, and outcomes of atrial fibrillation associated hospitalizations in patients with chronic kidney disease and end-stage renal disease..
242:45-60.
2021
-
Younger patients with chronic limb threatening ischemia face more frequent amputations..
242:6-14.
2021
-
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations..
241:38-49.
2021
-
Infective endocarditis and solid organ transplantation: Only worse outcomes during initial transplantation hospitalization..
240:63-72.
2021
-
A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study..
239:19-26.
2021
-
Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure..
239:110-119.
2021
-
Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus..
239:59-63.
2021
-
Estimating the real-world performance of the PROMISE minimal-risk tool..
239:100-109.
2021
-
Pre-operative atrial fibrillation and early right ventricular failure after left ventricular assist device implantation: a systematic review and meta-analysis..
239:120-128.
2021
-
The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease..
239:135-146.
2021
-
Electronic health record risk score provides earlier prognostication of clinical outcomes in patients admitted to the cardiac intensive care unit..
238:85-88.
2021
-
Financial burden, distress, and toxicity in cardiovascular disease..
238:75-84.
2021
-
Individuals aged 1-64 years with documented congenital heart defects at healthcare encounters, five U.S. surveillance sites, 2011-2013..
238:100-108.
2021
-
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial..
238:1-11.
2021
-
Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial..
237:68-78.
2021
-
Sex disparities in patients with symptomatic severe aortic stenosis..
237:116-126.
2021
-
Venous thromboembolism among patients hospitalized with COVID-19 at Veterans Health Administration Hospitals..
237:1-4.
2021
-
Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries..
236:37-48.
2021
-
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF..
236:4-12.
2021
-
Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program..
235:149-157.
2021
-
Red blood cell transfusion threshold and mortality in cardiac intensive care unit patients..
235:24-35.
2021
-
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities..
235:82-96.
2021
-
Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial..
233:1-4.
2021
-
Differences between patients with cardiovascular disease and cancer referred for palliative care..
233:5-9.
2021
-
Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update..
233:86-91.
2021
-
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators..
233:48-58.
2021
-
Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic..
233:122-131.
2021
-
Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement..
233:151-152.
2021
-
Risk markers of incident atrial fibrillation in patients with coronary heart disease..
233:92-101.
2021
-
Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States..
233:132-140.
2021
-
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials..
232:10-22.
2021
-
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial..
232:116-124.
2021
-
Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program..
232:71-83.
2021
-
Temporal trends in risk profiles among patients hospitalized for heart failure..
232:154-163.
2021
-
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial..
231:128-136.
2021
-
Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial..
231:18-24.
2021
-
Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care..
231:1-5.
2021
-
Left bundle-branch block is associated with asimilar dyssynchronous phenotype in heart failure patients with normal and reduced ejection fractions..
231:45-55.
2021
-
Outpatient versus observation/inpatient management of emergency department patients rapidly ruled-out for acute myocardial infarction: Findings from the HIGH-US study..
231:6-17.
2021
-
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction..
231:121-127.
2021
-
Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease..
231:36-44.
2021
-
Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock..
230:93-97.
2020
-
Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials..
230:71-81.
2020
-
Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer..
230:54-58.
2020
-
Getting cardiogenic shock patients to the right place-How initial intensive care unit triage decisions impact processes of care and outcomes..
230:66-70.
2020
-
In-hospital outcomes after bariatric surgery in patients with heart failure..
230:59-62.
2020
-
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure..
230:35-43.
2020
-
Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center..
230:25-34.
2020
-
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial..
229:118-120.
2020
-
Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure..
229:1-17.
2020
-
Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review..
229:52-60.
2020
-
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib)..
229:110-117.
2020
-
Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial..
228:91-97.
2020
-
Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry..
228:57-64.
2020
-
China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial..
227:47-55.
2020
-
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial..
227:100-106.
2020
-
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve..
227:91-99.
2020
-
Acute myocardial infarction under-diagnosis and mortality in a Tanzanian emergency department: A prospective observational study..
226:214-221.
2020
-
Back to the future-Are we ready for a randomized trial of surgical versus percutaneous revascularization in cardiogenic shock?.
226:264-266.
2020
-
Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?.
226:69-74.
2020
-
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial..
226:49-59.
2020
-
Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)..
226:85-93.
2020
-
Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines..
226:4-12.
2020
-
Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations..
226:13-23.
2020
-
Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease..
226:188-197.
2020
-
Smartphone 12-lead ECG-Exciting but must be handled with care..
226:269.
2020
-
The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients..
226:140-146.
2020
-
A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response..
225:3-9.
2020
-
Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey..
225:55-59.
2020
-
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events..
225:97-107.
2020
-
Associations between anthropometric indices and outcomes of congenital heart operations in infants and young children: An analysis of data from the Society of Thoracic Surgeons Database..
224:85-97.
2020
-
Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits..
224:47-53.
2020
-
COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial..
224:10-16.
2020
-
Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank..
224:138-147.
2020
-
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial..
224:129-137.
2020
-
Longitudinal study of anthropometry in Fontan survivors: Pediatric Heart Network Fontan study..
224:192-200.
2020
-
Racial disparities and democratization of health care: A focus on TAVR in the United States..
224:166-170.
2020
-
Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement..
224:171-181.
2020
-
Transcatheter aortic valve replacement for patients with severe bicuspid aortic stenosis..
224:105-112.
2020
-
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
2020
-
Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era..
223:87-97.
2020
-
Future research prioritization in cardiac resynchronization therapy..
223:48-58.
2020
-
Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial..
223:84-86.
2020
-
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation..
223:65-71.
2020
-
Specificity of administrative coding for older adults with acute heart failure hospitalizations..
223:1-2.
2020
-
Association of postoperative complications and outcomes following coronary artery bypass grafting..
222:220-228.
2020
-
Emergency department evaluation of chest pain among adult congenital heart disease patients..
222:191-198.
2020
-
Implementation of Best Practices-Developing and Optimizing Regional Systems of Stroke Care: Design and Methodology..
222:105-111.
2020
-
Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Network Registry..
222:8-14.
2020
-
Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients..
222:93-104.
2020
-
Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter..
222:26-29.
2020
-
Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system..
221:9-18.
2020
-
Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction..
221:125-135.
2020
-
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial..
221:1-8.
2020
-
Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?.
220:97-107.
2020
-
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF..
220:41-50.
2020
-
High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction..
220:137-144.
2020
-
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS..
220:82-88.
2020
-
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial..
220:51-58.
2020
-
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation..
220:145-154.
2020
-
Rationale and design of the STeroids to REduce Systemic inflammation after infant heart Surgery (STRESS) trial..
220:192-202.
2020
-
Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management..
220:29-40.
2020
-
Videos to reduce racial disparities in ICD therapy Via Innovative Designs (VIVID) trial: Rational, design and methodology..
220:59-67.
2020
-
Age, knowledge, preferences, and risk tolerance for invasive cardiac care..
219:99-108.
2020
-
Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS..
219:47-57.
2020
-
Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock..
219:1-8.
2020
-
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation..
219:21-30.
2020
-
Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease..
218:92-99.
2019
-
Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country..
218:32-45.
2019
-
Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials..
218:110-122.
2019
-
ISCHEMIA trial update..
218:8.
2019
-
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS..
218:57-65.
2019
-
Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial..
218:84-91.
2019
-
Same-day discharge among patients undergoing elective PCI: Insights from the VA CART Program..
218:75-83.
2019
-
Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trial-Study design and description of the intervention..
217:148-158.
2019
-
The subcutaneous implantable cardioverter-defibrillator in review..
217:131-139.
2019
-
Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease..
217:42-51.
2019
-
Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry..
216:53-61.
2019
-
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort..
216:117-124.
2019
-
Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry..
216:74-81.
2019
-
Identification, diagnosis, treatment, and in-hospital outcomes of acute pulmonary embolism: Results from a single integrated health system..
216:136-142.
2019
-
Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD)..
216:91-101.
2019
-
Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population..
215:12-19.
2019
-
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial..
215:106-113.
2019
-
Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry..
215:167-177.
2019
-
Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry..
214:184-193.
2019
-
Racial differences in long-term outcomes among black and white patients with drug-eluting stents..
214:46-53.
2019
-
Comorbidities and the decision to undergo or forego destination therapy left ventricular assist device implantation: An analysis from the Trial of a Shared Decision Support Intervention for Patients and their Caregivers Offered Destination Therapy for End-Stage Heart Failure (DECIDE-LVAD) study..
213:91-96.
2019
-
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)..
213:97-104.
2019
-
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial..
213:57-65.
2019
-
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II..
213:81-90.
2019
-
Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients..
212:101-112.
2019
-
Corrigendum to "association between the timing of surgery for complicated, left-sided infective endocarditis and survival", American HeartJournal 2019, volume 210, April 2019, pages 108-116..
212:165.
2019
-
Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study..
212:72-79.
2019
-
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers..
212:1-12.
2019
-
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)..
212:23-35.
2019
-
Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation..
211:77-89.
2019
-
Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry..
211:1-10.
2019
-
Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial..
211:60-67.
2019
-
Peripheral blood metabolite profiles associated with new onset atrial fibrillation..
211:54-59.
2019
-
Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial..
211:22-33.
2019
-
Association between the timing of surgery for complicated, left-sided infective endocarditis and survival..
210:108-116.
2019
-
Knowledge of myocardial infarction symptoms and perceptions of self-risk in Tanzania..
210:69-74.
2019
-
Stroke prevention in atrial fibrillation: Closing the gap..
210:29-38.
2019
-
Trends in cardiorespiratory fitness: The evolution of exercise treadmill testing at a single Academic Medical Center from 1970 to 2012..
210:88-97.
2019
-
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial..
208:65-73.
2019
-
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial..
208:123-131.
2019
-
Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial..
208:28-36.
2019
-
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction..
208:81-90.
2019
-
The association of pre- and posthospital medication adherence in myocardial infarction patients..
208:74-80.
2019
-
An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial..
207:49-57.
2019
-
Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial..
207:40-48.
2019
-
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study..
207:66-75.
2019
-
System-integrated technology-enabled model of care to improve the health of stroke patients in rural China: protocol for SINEMA-a cluster-randomized controlled trial..
207:27-39.
2019
-
Countering clinical inertia in lipid management: Expert workshop summary..
206:24-29.
2018
-
Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry..
206:131-133.
2018
-
Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease..
206:51-60.
2018
-
The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts..
206:61-71.
2018
-
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial..
205:1-11.
2018
-
Catheter ablation of rotational activity in atrial fibrillation: A barren oasis?.
205:142-144.
2018
-
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design..
205:42-52.
2018
-
Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION..
205:133-141.
2018
-
The First Brazilian Registry of Hypertension..
205:154-157.
2018
-
High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States..
204:151-155.
2018
-
The Association of Duration of participation in get with the guidelines-resuscitation with quality of Care for in-Hospital Cardiac Arrest..
204:156-162.
2018
-
Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry..
204:9-16.
2018
-
Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial..
204:163-173.
2018
-
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics..
203:30-38.
2018
-
Long-term outcomes of mitral regurgitation by type and severity..
203:39-48.
2018
-
Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device..
202:33-38.
2018
-
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial..
202:97-103.
2018
-
I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale..
202:109-115.
2018
-
Implications of a recurrent in-hospital cardiac arrest on survival and neurological outcomes..
202:139-143.
2018
-
Leveraging electronic health records for clinical research..
202:13-19.
2018
-
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis..
202:54-60.
2018
-
The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium..
202:104-108.
2018
-
The high cost of critical care unit over-utilization for patients with NSTE ACS..
202:84-88.
2018
-
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial..
202:89-96.
2018
-
Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction..
201:103-110.
2018
-
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome..
201:25-32.
2018
-
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design..
201:124-135.
2018
-
The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial..
201:164-167.
2018
-
The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients..
201:17-24.
2018
-
Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial..
201:40-48.
2018
-
A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure..
200:127-133.
2018
-
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial..
200:17-23.
2018
-
Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease..
200:96-101.
2018
-
Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs..
200:1-10.
2018
-
Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure..
200:134-140.
2018
-
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF..
200:102-109.
2018
-
Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study..
200:51-59.
2018
-
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial..
199:51-58.
2018
-
Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design..
199:192-199.
2018
-
Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery..
199:150-155.
2018
-
Effects of a 12-week mHealth program on peak VO2 and physical activity patterns after completing cardiac rehabilitation: A randomized controlled trial..
199:105-114.
2018
-
Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock..
199:181-191.
2018
-
Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial..
199:97-104.
2018
-
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)..
199:83-91.
2018
-
Telemedicine cardiovascular risk reduction in veterans: The CITIES trial..
199:122-129.
2018
-
The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure..
199:115-121.
2018
-
Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials..
199:44-50.
2018
-
Trends and outcomes of cardiac transplantation from donors dying of drug intoxication..
199:92-96.
2018
-
A "shocking" new code status..
198:1-3.
2018
-
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)..
198:152-159.
2018
-
Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction..
198:97-107.
2018
-
Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles..
198:18-24.
2018
-
Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry..
198:123-128.
2018
-
Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial..
198:129-134.
2018
-
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial..
198:145-151.
2018
-
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients..
198:84-90.
2018
-
A population health perspective on a claims and electronic health record-based tool to screen for suboptimal medication adherence..
197:150-152.
2018
-
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial..
197:1-8.
2018
-
Cognition and brain changes associated with high-dose atorvastatin: A BOLD proposition?.
197:163-165.
2018
-
Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program..
197:9-17.
2018
-
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial..
197:133-141.
2018
-
Access to routine care and risks for 30-day readmission in patients with cardiovascular disease..
196:9-17.
2018
-
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial..
196:28-35.
2018
-
How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?.
196:163-169.
2018
-
Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins..
196:131-143.
2018
-
Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs..
196:170-177.
2018
-
Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT)..
195:70-77.
2018
-
Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial..
195:108-114.
2018
-
Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry..
195:1-13.
2018
-
Enabling social listening for cardiac safety monitoring: Proceedings from a drug information association-cardiac safety research consortium cosponsored think tank..
194:107-115.
2017
-
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries..
194:132-140.
2017
-
Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease..
194:116-124.
2017
-
Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis..
193:46-54.
2017
-
Idarucizumab since FDA approval: Use in the real-world..
193:93-94.
2017
-
In-hospital cardiac arrest: Complex clinical challenges in need of unique solutions..
193:104-107.
2017
-
Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction..
192:e3.
2017
-
Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF)..
192:38-47.
2017
-
Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease..
192:13-18.
2017
-
Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure..
191:82-90.
2017
-
Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure..
191:75-81.
2017
-
Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort..
190:40-45.
2017
-
Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial..
190:113-122.
2017
-
Prevention of sudden cardiac death in the young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium..
190:123-131.
2017
-
Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale..
190:19-24.
2017
-
Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis..
190:135-139.
2017
-
Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients..
189:146-157.
2017
-
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry..
189:177-183.
2017
-
Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy..
189:75-84.
2017
-
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)..
189:40-47.
2017
-
Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol..
189:158-166.
2017
-
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial..
189:137-145.
2017
-
Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program..
189:85-93.
2017
-
The economics of PCSK-9 inhibitors..
189:200-201.
2017
-
When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials..
189:1-8.
2017
-
Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study..
188:175-185.
2017
-
Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score..
188:127-135.
2017
-
Corrigendum to 'Association of Standard Clinical and Laboratory Variables with Red Blood Cell Distribution Width (RDW)'[Am. Heart J. (2016) 22-28]..
188:196.
2017
-
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization..
188:156-166.
2017
-
Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials..
188:18-25.
2017
-
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome..
187:53-61.
2017
-
Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study..
187:19-28.
2017
-
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)..
187:1-9.
2017
-
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial..
187:62-69.
2017
-
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome..
187:194-203.
2017
-
Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium..
187:156-169.
2017
-
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics..
187:182-190.
2017
-
Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome..
187:112-121.
2017
-
Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial..
186:130-138.
2017
-
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes..
186:91-99.
2017
-
National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension..
186:29-39.
2017
-
Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial..
186:73-82.
2017
-
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial..
185:140-149.
2017
-
Cardioversion and subsequent quality of life and natural history of atrial fibrillation..
185:59-66.
2017
-
Population differences in associations of serotonin transporter promoter polymorphism (5HTTLPR) di- and triallelic genotypes with blood pressure and hypertension prevalence..
185:110-122.
2017
-
Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale..
185:130-139.
2017
-
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial..
185:93-100.
2017
-
An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial..
184:133-140.
2017
-
Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial..
184:88-96.
2017
-
Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial..
184:1-9.
2017
-
Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100]..
184:156.
2017
-
Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898]..
184:157.
2017
-
Effects of exercise and stress management training on nighttime blood pressure dipping in patients with coronary heart disease: A randomized, controlled trial..
183:85-90.
2017
-
Extending the volume-outcomes debate into the world of congenital cardiac catheterization..
183:115-117.
2017
-
Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes..
183:54-61.
2017
-
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study..
183:62-68.
2017
-
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale..
182:28-35.
2016
-
Identifying the frailty phenotype: The evidence for good enough..
182:144-145.
2016
-
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial..
182:62-71.
2016
-
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)..
182:89-96.
2016
-
Patient factors associated with quality of life in atrial fibrillation..
182:135-143.
2016
-
Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts..
182:103-110.
2016
-
Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry..
182:9-20.
2016
-
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study..
182:125-134.
2016
-
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease..
181:92-100.
2016
-
How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)..
181:145-152.
2016
-
Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention..
181:52-59.
2016
-
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction..
180:22-28.
2016
-
The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program..
180:74-81.
2016
-
Heart failure medications prescribed at discharge for patients with left ventricular assist devices..
179:99-106.
2016
-
Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure..
179:116-126.
2016
-
Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries..
179:10-18.
2016
-
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial..
179:77-86.
2016
-
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial..
178:1-8.
2016
-
Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry..
178:95-101.
2016
-
Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial..
178:74-84.
2016
-
Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE)..
178:198-205.
2016
-
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial..
178:176-184.
2016
-
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial..
178:55-64.
2016
-
Reactive hyperemia is associated with adverse clinical outcomes in heart failure..
178:108-114.
2016
-
The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database..
178:65-73.
2016
-
Comparison of risk scores for the prediction of stroke in African Americans: Findings from the Jackson Heart Study..
177:25-32.
2016
-
Contributors to and impact of residual shunting after device closure of atrial septal defects..
177:112-119.
2016
-
Geographic dispersion of TAVR services: Ensuring availability while maintaining quality..
177:160-162.
2016
-
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial..
177:1-8.
2016
-
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction..
177:33-41.
2016
-
The Cardiac Safety Research Consortium enters its second decade: An invitation to participate..
177:96-101.
2016
-
A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale..
176:107-113.
2016
-
Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry..
176:1-9.
2016
-
Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study..
176:10-16.
2016
-
The "rise of the rule out": The SPECTer of cardiac stress imaging..
176:122-124.
2016
-
Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial..
176:53-62.
2016
-
Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines..
175:1-8.
2016
-
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial..
175:86-93.
2016
-
Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?.
175:184-192.
2016
-
Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry..
175:28-35.
2016
-
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial..
175:175-183.
2016
-
The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China..
175:193-201.e3.
2016
-
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study..
174:120-128.
2016
-
Association of standard clinical and laboratory variables with red blood cell distribution width..
174:22-28.
2016
-
Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial..
174:7-13.
2016
-
Pooled analysis of adverse event collection from 4 acute coronary syndrome trials..
174:60-67.
2016
-
Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial..
174:147-153.
2016
-
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial..
174:103-110.
2016
-
Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry..
173:172-178.
2016
-
Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes..
173:57-66.
2016
-
Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease..
173:27-34.
2016
-
Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): Study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy followINg carDiac catheterization) trial..
172:88-95.
2016
-
Evaluation of a provocative dyspnea severity score in acute heart failure..
172:34-41.
2016
-
Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction..
172:9-18.
2016
-
Practice gaps in the care of mitral valve regurgitation: Insights from the American College of Cardiology mitral regurgitation gap analysis and advisory panel..
172:70-79.
2016
-
Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?.
172:42-44.
2016
-
Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative..
172:64-69.
2016
-
The role of diabetes mellitus in the composition of coronary thrombi in patients presenting with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention..
172:26-33.
2016
-
Untangling the paradox: Obesity as prognostic marker in prevalent cardiovascular disease..
172:170-172.
2016
-
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction..
171:25-32.
2016
-
Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet)..
171:64-72.e1-2.
2016
-
Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization"..
171:e7.
2016
-
An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS)..
170:1077-1085.
2015
-
Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan..
170:1227-1233.
2015
-
Differences in health care use and outcomes by the timing of in-hospital worsening heart failure..
170:1124-1132.
2015
-
Validation of the modified Sgarbossa criteria for acute coronary occlusion in the setting of left bundle branch block: A retrospective case-control study..
170:1255-1264.
2015
-
A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial..
170:929-937.
2015
-
Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction..
170:855-864.
2015
-
Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial..
170:986-994.e5.
2015
-
Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience..
170:872-879.
2015
-
Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis..
170:923-928.
2015
-
The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison..
170:1050-1059.e3.
2015
-
Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure..
170:951-960.
2015
-
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial..
170:683-694.e3.
2015
-
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)..
170:675-682.e8.
2015
-
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial..
170:695-705.e5.
2015
-
Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement..
170:821-829.
2015
-
Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events..
170:598-605.e7.
2015
-
Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)..
170:455-64.e5.
2015
-
Genome-wide association study of new-onset atrial fibrillation after coronary artery bypass grafting surgery..
170:580-90.e28.
2015
-
High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction..
170:550-558.
2015
-
Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts study..
170:438-46.e44.
2015
-
Use of outcome measures in pulmonary hypertension clinical trials..
170:419-29.e3.
2015
-
Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization..
170:400-408.
2015
-
Better survival for victims of cardiac arrest occurring in sports facilities: From speculations to facts..
170:200-201.
2015
-
Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy..
170:371-379.
2015
-
Diuretic response in acute heart failure-an analysis from ASCEND-HF..
170:313-321.
2015
-
Evaluation of Selvester QRS score for use in presence of conduction abnormalities in a broad population..
170:346-352.
2015
-
Letter response..
170:e5-e6.
2015
-
Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models..
170:290-297.
2015
-
Primary prevention implantable cardioverter defibrillators in women: More questions than answers..
170:197-199.
2015
-
The association of in-hospital guideline adherence and longitudinal postdischarge mortality in older patients with non-ST-segment elevation myocardial infarction..
170:273-280.e1.
2015
-
Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)..
170:298-305.
2015
-
Delirium is a robust predictor of morbidity and mortality among critically ill patients treated in the cardiac intensive care unit..
170:79-86.e1.
2015
-
Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry..
170:55-61.
2015
-
Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care..
170:36-45.11.
2015
-
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry..
170:141-148.e1.
2015
-
Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study..
170:62-69.
2015
-
Effectiveness of implantable cardioverter-defibrillators in survivors of inhospital cardiac arrest..
169:870-878.e1.
2015
-
Geographic variation in the use of catheter ablation for atrial fibrillation among Medicare beneficiaries..
169:775-782.e2.
2015
-
Rationale and design of a cluster-randomized multifaceted intervention trial to improve stroke care quality in China: The GOLDEN BRIDGE-Acute Ischemic Stroke..
169:767-774.e2.
2015
-
Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial..
169:890-898.e1.
2015
-
Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis..
169:924-937.e3.
2015
-
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations..
169:743-750.
2015
-
Variation in performance measure criteria significantly affects cardiology practice rankings: Insights from the National Cardiovascular Data Registry's Practice Innovation and Clinical Excellence Registry..
169:847-853.
2015
-
Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)..
169:647-654.e2.
2015
-
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo..
169:631-638.e7.
2015
-
A nationwide survey on perception, experience, and expectations of hybrid coronary revascularization among top-ranked US hospitals..
169:557-63.e6.
2015
-
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial..
169:531-538.
2015
-
Authorship in a multicenter clinical trial: The Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) scoring system results..
169:457-63.e6.
2015
-
Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry..
169:515-22.e1.
2015
-
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study..
169:496-507.e1.
2015
-
Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients..
169:539-548.
2015
-
Transitions at the american heart journal..
169:445.
2015
-
A reappraisal of loop diuretic choice in heart failure patients..
169:323-333.
2015
-
Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction..
169:404-411.e3.
2015
-
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators..
169:305-314.
2015
-
Incidence of strict versus nonstrict left bundle branch block after transcatheter aortic valve replacement..
169:438-444.
2015
-
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials..
169:315-322.
2015
-
Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: design and rationale of the ROADMAP clinical trial..
169:205-210.e20.
2015
-
The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study..
169:274-281.e1.
2015
-
Translation of acute coronary syndrome therapies: from evidence to routine clinical practice..
169:266-273.
2015
-
Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke..
169:39-44.e2.
2015
-
Anger and mental stress-induced myocardial ischemia: mechanisms and clinical implications..
169:4-5.
2015
-
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial..
169:25-30.
2015
-
Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project..
169:122-31.e22.
2015
-
Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial..
169:175-184.
2015
-
P-wave indices and atrial fibrillation: cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study..
169:53-61.e1.
2015
-
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment..
169:186-187.
2015
-
Targeted versus standard feedback: results from a randomized quality improvement trial..
169:132-41.e2.
2015
-
Reducing the burden of disease and death from familial hypercholesterolemia: a call to action..
168:807-811.
2014
-
Transient and persistent worsening renal function during hospitalization for acute heart failure..
168:891-900.
2014
-
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial..
168:869-77.e1.
2014
-
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?.
168:611-621.
2014
-
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial..
168:682-689.
2014
-
How can we optimize the processes of care for acute coronary syndromes to improve outcomes?.
168:622-631.
2014
-
Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population..
168:721-730.
2014
-
Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials..
168:757-765.
2014
-
The association of myocardial infarction process of care measures and in-hospital mortality: a report from the NCDR®..
168:766-775.
2014
-
The palliative care in heart failure trial: rationale and design..
168:645-651.e1.
2014
-
Clinical outcomes of hybrid coronary revascularization versus coronary artery bypass surgery in patients with diabetes mellitus..
168:471-478.
2014
-
Design and rationale of the ANALYZE ST study: a prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients..
168:424-429.e1.
2014
-
Differences in sex-related bleeding and outcomes after percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) registry..
168:552-559.
2014
-
PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies..
168:495-502.e4.
2014
-
Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis..
168:530-536.
2014
-
Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention..
168:503-511.e2.
2014
-
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)..
168:487-494.
2014
-
The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial..
168:446-456.
2014
-
Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration..
168:405-413.e2.
2014
-
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)..
168:588-596.
2014
-
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012..
168:239-247.e1.
2014
-
Current quality of cardiovascular prevention for Million Hearts: an analysis of 147,038 outpatients from The Guideline Advantage..
168:398-404.
2014
-
Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial..
168:303-309.
2014
-
The use of aortic counterpulsation in United States: what can we learn from administrative databases?.
168:237-238.
2014
-
A critical review of hemodynamic changes and left ventricular remodeling after surgical aortic valve replacement and percutaneous aortic valve replacement..
168:150-9.e1-7.
2014
-
Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes..
168:182-8.e1.
2014
-
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries..
168:142-149.
2014
-
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population..
168:205-12.e1.
2014
-
Independent data monitoring committees: preparing a path for the future..
168:135-41.e1.
2014
-
Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome..
168:189-96.e1.
2014
-
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry..
168:160-167.
2014
-
Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry..
168:213-9.e1.
2014
-
Rationale and design of the AngeLmed for Early Recognition and Treatment of STEMI trial: a randomized, prospective clinical investigation..
168:168-174.
2014
-
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy..
168:37-44.e5.
2014
-
Nocturnal patterns of heart rate and the risk of mortality after acute myocardial infarction..
168:117-125.
2014
-
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study..
168:96-102.e2.
2014
-
Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov..
167:921-9.e2.
2014
-
Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction..
167:840-845.
2014
-
PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial..
167:796-803.e1.
2014
-
Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice..
167:846-52.e2.
2014
-
Proceedings from Duke resistant hypertension think tank..
167:775-88.e1.
2014
-
Response to letter to the editor by Lin et al..
167:e21.
2014
-
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention..
167:833-839.
2014
-
Clinical perspectives on reperfusion injury in acute myocardial infarction..
167:637-645.
2014
-
Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease..
167:697-706.e2.
2014
-
Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction?.
167:762-769.
2014
-
Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)..
167:735-42.e2.
2014
-
Health City Cayman Islands and the globalization of health services delivery..
167:770-774.
2014
-
Association of the ankle-brachial index with history of myocardial infarction and stroke..
167:499-505.
2014
-
Clinical outcomes after hybrid coronary revascularization versus coronary artery bypass surgery: a meta-analysis of 1,190 patients..
167:585-592.
2014
-
Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia: systematic review of revascularization in critical limb ischemia..
167:489-498.e7.
2014
-
Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study..
167:472-479.e5.
2014
-
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry..
167:601-609.e1.
2014
-
Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era..
167:576-584.e2.
2014
-
Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction..
167:480-488.e1.
2014
-
The association between body mass index and coronary artery disease severity: a comparison of black and white patients..
167:514-520.
2014
-
The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice..
167:466-471.
2014
-
Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction..
167:369-375.e2.
2014
-
Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry..
167:393-400.e1.
2014
-
Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease..
167:355-362.e3.
2014
-
Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry..
167:342-349.e17.
2014
-
Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: insights from the National Cardiovascular Data Registry (NCDR)..
167:350-354.
2014
-
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study..
167:335-341.
2014
-
Comparison of automated measurements of electrocardiographic intervals and durations by computer-based algorithms of digital electrocardiographs..
167:150-159.e1.
2014
-
Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction..
167:267-273.e1.
2014
-
The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure..
167:193-202.e1.
2014
-
Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction..
167:369-375.e2.
2014
-
Regional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: design and methodology..
167:15-21.e3.
2014
-
Trends in outcomes among older patients with non-ST-segment elevation myocardial infarction..
167:36-42.e1.
2014
-
Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry..
166:1043-1049.e1.
2013
-
Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database..
166:1050-1055.
2013
-
Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry..
166:1027-1034.
2013
-
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease..
166:983-989.e7.
2013
-
Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry..
166:1063-1071.e3.
2013
-
The association between smoking and long-term outcomes after non-ST-segment elevation myocardial infarction in older patients..
166:1056-1062.
2013
-
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial..
166:953-959.e3.
2013
-
Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation..
166:871-878.
2013
-
Cardiac biomarker measurement after elective percutaneous coronary interventions in older patients: insights from the National Cardiovascular Data Registry..
166:927-934.
2013
-
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial..
166:935-40.e1.
2013
-
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study..
166:913-919.
2013
-
Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy..
166:864-870.
2013
-
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial..
166:723-728.
2013
-
Impact of choice of imaging modality accompanying outpatient exercise stress testing on outcomes and resource use after revascularization for acute coronary syndromes..
166:783-791.e4.
2013
-
Learning from recent trials and shaping the future of acute heart failure trials..
166:629-635.
2013
-
Multistate implementation of guideline-based cardiac resuscitation systems of care: description of the HeartRescue project..
166:647-653.e2.
2013
-
Responding to the letter to the editor by Saver..
166:e39.
2013
-
Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG)..
166:709-715.
2013
-
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial..
166:549-558.
2013
-
Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial..
166:559-565.
2013
-
Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women)..
166:421-428.
2013
-
Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION)..
166:488-495.
2013
-
Regional systems of care for ST-elevation myocardial infarction: do they save lives?.
166:389-391.
2013
-
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial..
166:466-473.
2013
-
The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time?.
166:409-413.
2013
-
Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM)..
166:349-356.
2013
-
Left bundle-branch block: the relationship between electrocardiogram electrical activation and echocardiography mechanical contraction..
166:340-348.
2013
-
Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock..
166:298-305.
2013
-
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct..
166:208-216.e28.
2013
-
Results of a reevaluation of cardiovascular outcomes in the RECORD trial..
166:240-249.e1.
2013
-
The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?.
166:333-339.
2013
-
Educational videos to reduce racial disparities in ICD therapy via innovative designs (VIVID): a randomized clinical trial..
166:157-163.
2013
-
Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading..
166:95-103.
2013
-
The Cholesterol, Hypertension, And Glucose Education (CHANGE) study: results from a randomized controlled trial in African Americans with diabetes..
166:179-186.
2013
-
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study..
165:854-861.e2.
2013
-
Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days..
165:987-994.e1.
2013
-
Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors..
165:949-955.e3.
2013
-
Cardiovascular clinical research in South America..
165:848-853.
2013
-
Left ventricular mechanical dyssynchrony by cardiac magnetic resonance is greater in patients with strict vs nonstrict electrocardiogram criteria for left bundle-branch block..
165:956-963.
2013
-
Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment..
165:862-868.
2013
-
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome..
165:918-925.e2.
2013
-
Rescuing clinical trials in the United States and beyond: a call for action..
165:837-847.
2013
-
Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery..
165:1000-1007.
2013
-
Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure..
165:979-986.e1.
2013
-
High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease..
165:809-815.e1.
2013
-
Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches..
165:644-654.e1.
2013
-
Saphenous vein graft failure and clinical outcomes: toward a surrogate end point in patients following coronary artery bypass surgery?.
165:639-643.
2013
-
Thienopyridine efficacy and cigarette smoking status..
165:693-703.
2013
-
Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial..
165:761-769.
2013
-
Variability in performance measures for assessment of hypertension control..
165:823-827.
2013
-
Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation..
165:567-574.e6.
2013
-
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy..
165:583-590.e1.
2013
-
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry..
165:622-629.
2013
-
Response to "Global cardiovascular clinical trials and geographic altitude"..
165:e15.
2013
-
Telemedicine cardiovascular risk reduction in veterans..
165:501-508.
2013
-
The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles..
165:531-536.
2013
-
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention..
165:354-62.e2.
2013
-
Incidence of heart failure and mortality after acute coronary syndromes..
165:379-85.e2.
2013
-
Prehospital system delay in ST-segment elevation myocardial infarction care: a novel linkage of emergency medicine services and in hospital registry data..
165:363-370.
2013
-
TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium..
165:344-53.e1.
2013
-
Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial..
165:226-233.
2013
-
Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION)..
165:193-199.
2013
-
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial..
165:216-225.
2013
-
Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks..
165:123-132.
2013
-
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel..
165:176-182.
2013
-
Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction..
165:43-49.
2013
-
Diagnostic time course, treatment, and in-hospital outcomes for patients with ST-segment elevation myocardial infarction presenting with nondiagnostic initial electrocardiogram: a report from the American Heart Association Mission: Lifeline program..
165:50-56.
2013
-
In Reply: B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the ADHERE registry..
165:e3.
2013
-
Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction..
165:26-33.e3.
2013
-
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial..
164:884-92.e2.
2012
-
Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction..
164:846-855.
2012
-
Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure..
164:862-868.
2012
-
Risk stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studies..
164:825-834.
2012
-
Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction..
164:763-770.e3.
2012
-
Cardiac conduction system disease after transcatheter aortic valve replacement..
164:664-671.
2012
-
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI..
164:689-697.e3.
2012
-
Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications..
164:750-755.e1.
2012
-
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study..
164:728-734.
2012
-
Regionalization of ST-segment elevation myocardial infarction care: a task unfinished..
164:633-635.
2012
-
The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale..
164:646-653.e3.
2012
-
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients..
164:607-615.
2012
-
Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction..
164:502-508.
2012
-
Pediatric cardiovascular safety: challenges in drug and device development and clinical application..
164:481-492.
2012
-
Red versus white thrombi in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: clinical and angiographic outcomes..
164:553-560.
2012
-
A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) trial..
164:320-326.
2012
-
A proposal for new clinical concepts in the management of atrial fibrillation..
164:292-302.e1.
2012
-
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results..
164:379-386.e1.
2012
-
Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation..
164:373-378.
2012
-
Implications of geographical variation on clinical outcomes of cardiovascular trials..
164:303-312.
2012
-
Preferences of people with advanced heart failure-a structured narrative literature review to inform decision making in the palliative care setting..
164:313-319.e5.
2012
-
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial..
164:334-342.e1.
2012
-
Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: results from the Duke Databank for Cardiovascular Disease (DDCD)..
164:434-441.
2012
-
Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia..
164:277-284.
2012
-
Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial..
164:138-145.
2012
-
Evaluating the effectiveness of a rapidly adopted cardiovascular technology with administrative data: the case of drug-eluting stents for acute coronary syndromes..
164:207-214.
2012
-
Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: stratification according to renal function..
164:52-7.e1.
2012
-
Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I..
164:117-124.
2012
-
Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial..
164:43-51.
2012
-
Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies..
164:35-42.
2012
-
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)..
163:931-937.e1.
2012
-
B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry..
163:994-1001.
2012
-
Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure..
163:946-953.e1.
2012
-
Economic evaluation of telephone self-management interventions for blood pressure control..
163:980-986.
2012
-
Racial differences in hospice use and patterns of care after enrollment in hospice among Medicare beneficiaries with heart failure..
163:987-993.e3.
2012
-
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization..
163:777-782.e8.
2012
-
Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease..
163:844-850.e1.
2012
-
International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation..
163:804-811.
2012
-
Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction..
163:783-789.
2012
-
Physical function and independence 1 year after myocardial infarction: observations from the Translational Research Investigating Underlying disparities in recovery from acute Myocardial infarction: Patients' Health status registry..
163:790-796.
2012
-
Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines..
163:894-899.
2012
-
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial..
163:797-803.
2012
-
Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension..
163:589-594.
2012
-
Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial..
163:657-65.e1.
2012
-
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction..
163:720-728.
2012
-
Simple regional strain pattern analysis to predict response to cardiac resynchronization therapy: rationale, initial results, and advantages..
163:697-704.
2012
-
The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction..
163:705-713.
2012
-
A multifaceted intervention to narrow the evidence-based gap in the treatment of acute coronary syndromes: rationale and design of the Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes (BRIDGE-ACS) cluster-randomized trial..
163:323-329.e1.
2012
-
Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit..
163:392-398.e1.
2012
-
Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database..
163:365-371.
2012
-
Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction..
163:372-382.
2012
-
Downstream procedures and outcomes after stress testing for chest pain without known coronary artery disease in the United States..
163:454-461.
2012
-
Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial..
163:438-445.
2012
-
Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT)..
163:462-469.
2012
-
Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction..
163:430-437.e3.
2012
-
Design of the RELAXin in acute heart failure study..
163:149-55.e1.
2012
-
Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure..
163:239-45.e3.
2012
-
Design of the Trial to Assess Chelation Therapy (TACT)..
163:7-12.
2012
-
Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF..
163:49-56.e2.
2012
-
Nonfatal myocardial infarction and long-term outcomes in coronary artery disease..
163:95-103.
2012
-
Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure..
163:88-94.e3.
2012
-
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial..
163:20-26.
2012
-
Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology-findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study..
162:1003-1010.
2011
-
Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines-Coronary Artery Disease (GWTG-CAD) registry..
162:988-995.e4.
2011
-
The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial..
162:996-1002.
2011
-
Trends and predictors of length of stay after primary percutaneous coronary intervention: a report from the CathPCI registry..
162:1052-1061.
2011
-
Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry..
162:860-869.e1.
2011
-
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program..
162:900-906.
2011
-
LV twisting and untwisting in HCM: ejection begets filling. Diastolic functional aspects of HCM..
162:798-810.
2011
-
Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score..
162:875-883.e1.
2011
-
Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site..
162:826-831.
2011
-
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function..
162:884-892.e1.
2011
-
Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research..
162:844-851.
2011
-
Trends in the use of diagnostic coronary angiography, percutaneous coronary intervention, and coronary artery bypass graft surgery across North Carolina..
162:932-937.
2011
-
A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction..
162:654-662.e1.
2011
-
Downstream coronary effects of drug-eluting stents..
162:764-771.e1.
2011
-
Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke..
162:692-699.e2.
2011
-
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF..
162:606-612.e1.
2011
-
Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure..
162:480-6.e3.
2011
-
Medication adherence: a call for action..
162:412-424.
2011
-
Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: implications for strategic management..
162:436-443.
2011
-
The need for transformative innovation in hypertension management..
162:405-411.
2011
-
Hospital-acquired anemia and in-hospital mortality in patients with acute myocardial infarction..
162:300-309.e3.
2011
-
Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)..
162:283-290.e2.
2011
-
Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice..
162:222-231.
2011
-
Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian population..
162:291-299.
2011
-
A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial..
162:47-55.e1.
2011
-
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"..
162:89-97.
2011
-
Do East Asians have different hypercoagulable states compared with Western population?.
162:e19-e20.
2011
-
Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use..
162:166-72.e1.
2011
-
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies..
162:160-165.
2011
-
Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration..
162:64-73.
2011
-
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality..
161:1024-30.e3.
2011
-
Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial..
161:1038-1045.
2011
-
Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome..
161:855-863.
2011
-
Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: an academic model for countering the epidemic..
161:842-847.
2011
-
Do heart failure disease management programs make financial sense under a bundled payment system?.
161:916-922.
2011
-
From batting average to wins above replacement to composite end points-refining clinical research using baseball statistical methods..
161:805-806.
2011
-
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial..
161:848-854.
2011
-
Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: results from the American College of Cardiology's NCDR(®)..
161:864-870.
2011
-
Was the role of statins in slowing the progression of abdominal aortic aneurysms underestimated?.
161:e29.
2011
-
Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure..
161:746-754.
2011
-
No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction..
161:657-663.e1.
2011
-
Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk..
161:782-789.
2011
-
Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry..
161:689-697.
2011
-
The effectiveness of personalized coronary heart disease and stroke risk communication..
161:673-680.
2011
-
Angina frequency after myocardial infarction and quality of life in older versus younger adults: the Prospective Registry Evaluating Myocardial Infarction: Event and Recovery study..
161:631-638.
2011
-
Cardiovascular research in India: a perspective..
161:431-438.
2011
-
High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration..
161:500-507.e1.
2011
-
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy..
161:487-493.
2011
-
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy..
161:598-604.
2011
-
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial..
161:261-268.e1-2.
2011
-
Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients..
161:241-246.
2011
-
Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase..
161:224-232.
2011
-
Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial..
161:391-396.
2011
-
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial..
161:298-306.e1.
2011
-
Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry..
161:360-366.
2011
-
Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study..
161:233-240.
2011
-
The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST..
161:283-290.
2011
-
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG)..
161:418-424.e1-3.
2011
-
Arrhythmias in patients with hypoplastic left heart syndrome..
161:138-144.
2011
-
Clinical research careers: reports from a NHLBI pediatric heart network clinical research skills development conference..
161:13-67.
2011
-
Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: a report from the national cardiovascular data registry..
161:76-83.e1.
2011
-
Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT)..
161:84-90.
2011
-
PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing..
161:165-171.
2011
-
Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score..
161:113-122.e2.
2011
-
Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction..
161:91-97.
2011
-
Anthropometric measures after Fontan procedure: implications for suboptimal functional outcome..
160:1092-1098.e1.
2010
-
Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative..
160:1072-1078.
2010
-
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux..
160:1029-1034.e1.
2010
-
Linking clinical registry data with administrative data using indirect identifiers: implementation and validation in the congenital heart surgery population..
160:1099-1104.
2010
-
Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry..
160:1121-1129.e1.
2010
-
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY..
160:1056-1064.e2.
2010
-
Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure..
160:1142-1148.
2010
-
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions..
160:1035-1041.e1.
2010
-
The Cardiac Safety Research Consortium electrocardiogram warehouse: thorough QT database specifications and principles of use for algorithm development and testing..
160:1023-1028.
2010
-
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG)..
160:1130-1136.e3.
2010
-
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial..
160:795-803.e2.
2010
-
Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries..
160:885-892.
2010
-
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease..
160:785-794.e10.
2010
-
Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry..
160:819-825.
2010
-
Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure..
160:928-933.
2010
-
Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies..
160:605-618.
2010
-
Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])..
160:649-654.
2010
-
Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: a Cardiac Safety Research Consortium "Incubator" Think Tank..
160:619-626.
2010
-
Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial..
160:671-677.
2010
-
Dronedarone and vitamin K antagonists: a review of drug-drug interactions..
160:577-582.
2010
-
Electrocardiographic assessment for therapeutic proteins--scientific discussion..
160:627-634.
2010
-
Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial..
160:678-684.
2010
-
Racial differences in long-term survival among patients with coronary artery disease..
160:744-751.
2010
-
Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era..
160:767-774.
2010
-
Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non-ST-segment elevation myocardial infarction..
160:405-411.
2010
-
Left ventricular dysfunction as a risk factor for cardiovascular and noncardiovascular hospitalizations in African Americans..
160:488-495.
2010
-
Predictors of 90-day readmission among patients with acute severe hypertension. The cross-sectional observational Studying the Treatment of Acute hyperTension (STAT) study..
160:521-527.e1.
2010
-
Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study..
160:371-379.e2.
2010
-
A review of dyspnea in acute heart failure syndromes..
160:209-214.
2010
-
Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events..
160:346-354.
2010
-
Economic analysis of a tailored behavioral intervention to improve blood pressure control for primary care patients..
160:257-263.
2010
-
Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy..
160:272-278.
2010
-
Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure..
160:132-138.e1.
2010
-
Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age..
160:122-131.
2010
-
Leveraging observational registries to inform comparative effectiveness research..
160:8-15.
2010
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)..
160:65-72.
2010
-
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial..
160:16-22.e1.
2010
-
The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation..
160:23-29.
2010
-
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study..
160:30-35.e1.
2010
-
Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines program..
159:1026-1036.
2010
-
Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction..
159:998-1004.e2.
2010
-
Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28..
159:964-971.e1.
2010
-
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial..
159:988-997.
2010
-
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design..
159:705-709.
2010
-
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program..
159:841-849.e1.
2010
-
Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development..
159:716-729.
2010
-
Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance"..
159:744-748.
2010
-
Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative..
159:757-763.
2010
-
Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project..
159:730-736.e2.
2010
-
Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial..
159:899-904.
2010
-
ST2 and mortality in non-ST-segment elevation acute coronary syndrome..
159:788-794.
2010
-
Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients..
159:508-517.e1.
2010
-
Changes in beliefs about medications during long-term care for ischemic heart disease..
159:561-569.
2010
-
Electronic health records and quality of care for heart failure..
159:635-642.e1.
2010
-
Quality of life effects of automatic external defibrillators in the home: results from the Home Automatic External Defibrillator Trial (HAT)..
159:627-634.e7.
2010
-
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale..
159:331-339.
2010
-
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database..
159:462-470.e1.
2010
-
In-hospital management of patients with atrial flutter..
159:370-376.
2010
-
Relationships between emerging measures of heart failure processes of care and clinical outcomes..
159:406-413.
2010
-
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study..
159:340-347.e1.
2010
-
Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals..
159:207-214.
2010
-
Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)..
159:222-230.e2.
2010
-
Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)..
159:238-244.
2010
-
Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease?.
159:141-147.
2010
-
Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium "Incubator" Think Tank..
159:17-24.
2010
-
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial..
159:131-140.
2010
-
Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF..
158:956-964.
2009
-
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry..
158:1038-1045.
2009
-
Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease..
158:933-940.
2009
-
Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure..
158:965-971.
2009
-
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial..
158:998-1004.e1.
2009
-
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group..
158:881-886.e1.
2009
-
Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative..
158:748-754.e1.
2009
-
Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial..
158:755-760.
2009
-
Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial..
158:726-733.
2009
-
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial..
158:792-798.
2009
-
Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository..
158:719-725.
2009
-
Reporting and representation of race/ethnicity in published randomized trials..
158:742-747.
2009
-
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy..
158:784.e1-784.e6.
2009
-
Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF)..
158:644-652.
2009
-
Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative..
158:688-694.
2009
-
Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial..
158:S53-S63.
2009
-
N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study..
158:S37-S44.
2009
-
New York Heart Association functional class predicts exercise parameters in the current era..
158:S24-S30.
2009
-
Outcomes, health policy, and managed care: relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure..
158:S64-S71.
2009
-
Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry..
158:599-606.e1.
2009
-
Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery..
158:680-687.
2009
-
Relationship of age and exercise performance in patients with heart failure: the HF-ACTION study..
158:S6-S15.
2009
-
Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction..
158:S72-S77.
2009
-
Understanding heart failure through the HF-ACTION baseline characteristics..
158:S1-S5.
2009
-
Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials..
158:422-430.
2009
-
Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative..
158:317-326.
2009
-
Heart failure disease management program experience in 4,545 heart failure admissions to a community hospital..
158:459-466.
2009
-
The Cholesterol, Hypertension, and Glucose Education (CHANGE) study for African Americans with diabetes: study design and methodology..
158:342-348.
2009
-
Weekend hospital admission and discharge for heart failure: association with quality of care and clinical outcomes..
158:451-458.
2009
-
Correlation of impedance cardiography with invasive hemodynamic measurements in patients with advanced heart failure: the BioImpedance CardioGraphy (BIG) substudy of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial..
158:217-223.
2009
-
Pulmonary artery catheterization in patients with acute coronary syndromes..
158:170-176.
2009
-
The paradoxical use of cardiac catheterization in patients with non-ST-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guidelines (CRUSADE) Quality Improvement Initiative..
158:263-270.
2009
-
Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: data from the Mode Selection Trial (MOST)..
158:78-83.e2.
2009
-
Renal function, atherothrombosis extent, and outcomes in high-risk patients..
158:141-148.e1.
2009
-
Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the Society of Thoracic Surgeons..
158:47-52.
2009
-
Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF)..
157:1010-1017.
2009
-
Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)..
157:1018-1025.
2009
-
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers..
157:995-1000.
2009
-
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group..
157:957-970.
2009
-
Regulatory and ethical considerations for linking clinical and administrative databases..
157:971-982.
2009
-
Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events..
157:1097-1105.
2009
-
Insulin resistance independently predicts the progression of coronary artery calcification..
157:939-945.
2009
-
New precompetitive paradigms: focus on cardiac safety..
157:825-826.
2009
-
Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry..
157:926-932.
2009
-
Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial..
157:837-844.e3.
2009
-
Risk assessment in the genomic era: are we missing the low-hanging fruit?.
157:799-801.
2009
-
TREATING DEPRESSION IN PATIENTS WITH HEART DISEASE: Is the Glass Half Empty or Half Full?.
157:e35-e37.
2009
-
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial..
157:599-605.
2009
-
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry..
157:651-657.
2009
-
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography..
157:716-723.
2009
-
Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF..
157:754-62.e2.
2009
-
Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative..
157:525-531.
2009
-
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk..
157:502-508.
2009
-
Patient education and provider decision support to control blood pressure in primary care: a cluster randomized trial..
157:450-456.
2009
-
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics..
157:428-435.e2.
2009
-
Common endothelial progenitor cell assays identify discrete endothelial progenitor cell populations..
157:335-344.
2009
-
Contrast-enhanced magnetic resonance imaging identifies focal regions of intramyocardial fibrosis in patients with severe aortic valve disease: Correlation with quantitative histopathology..
157:361-368.
2009
-
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)..
157:271-277.
2009
-
Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)..
157:219-228.
2009
-
Ethnic differences in the treatment of depression in patients with ischemic heart disease..
157:77-83.
2009
-
Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR)..
157:141-148.
2009
-
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines..
157:111-117.e2.
2009
-
Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle..
157:37-45.
2009
-
The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure..
157:84-90.
2009
-
Trends from 1987 to 2004 in sudden death due to coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study..
157:46-52.
2009
-
Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure..
156:1170-1176.
2008
-
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy..
156:1080-1088.e1.
2008
-
Discrimination: a new cardiovascular risk factor?.
156:1023-1025.
2008
-
Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)..
156:1196-1200.
2008
-
Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure..
156:1191-1195.
2008
-
Sex differences in patients seeking medical attention for prodromal symptoms before an acute coronary event..
156:1210-1216.e1.
2008
-
Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006..
156:1045-1055.
2008
-
Clopidogrel use and bleeding after coronary artery bypass graft surgery..
156:886-892.
2008
-
Considerations of net present value in policy making regarding diagnostic and therapeutic technologies..
156:879-885.
2008
-
Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007..
156:816-825.e1.
2008
-
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis..
156:855-863.e2.
2008
-
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes..
156:826-832.
2008
-
Rationale, design, and baseline characteristics of a Program to Assess and Review Trending INformation and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF)..
156:833-839.e2.
2008
-
Clinical characteristics associated with poor long-term survival among patients with diabetes mellitus undergoing saphenous vein graft interventions..
156:728-735.
2008
-
Effects of disclosing financial interests on participation in medical research: a randomized vignette trial..
156:689-697.
2008
-
Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial..
156:698-705.
2008
-
Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)..
156:662-673.
2008
-
Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention..
156:613-622.
2008
-
Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study..
156:674-681.
2008
-
The economic returns of pediatric clinical trials of antihypertensive drugs..
156:682-688.
2008
-
Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure..
156:437-444.
2008
-
Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE)..
156:606-612.
2008
-
Postmarket evaluation of breakthrough technologies..
156:201-208.
2008
-
Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments..
156:248-255.
2008
-
Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes..
156:209-215.
2008
-
Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals..
156:185-192.
2008
-
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale..
156:44-56.
2008
-
Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program..
155:1059-1067.
2008
-
Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial)..
155:1090-1096.
2008
-
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes..
155:1047-1053.
2008
-
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005..
155:829-840.
2008
-
Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions..
155:781-790.
2008
-
The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study..
155:823-828.
2008
-
The influence of age on health status outcomes after acute myocardial infarction..
155:855-861.
2008
-
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale..
155:600-608.
2008
-
Delivering heart failure disease management in 3 tertiary care centers: key clinical components and venues of care..
155:764.e1-764.e5.
2008
-
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome..
155:725-731.
2008
-
Highlights from American Heart Association, November 4-7, 2007, Orlando, Florida, USA. Late-breaking trials summary..
155:615-623.
2008
-
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues..
155:435-444.
2008
-
Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies..
155:418-434.
2008
-
Noninvasive, medical management for non-ST-elevation acute coronary syndromes..
155:397-407.
2008
-
Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)..
155:501-506.
2008
-
Rationale and design of the Home Automatic External Defibrillator Trial (HAT)..
155:445-454.
2008
-
Weight change after myocardial infarction--the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) experience..
155:478-484.
2008
-
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes..
155:369-374.
2008
-
Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry..
155:361-368.
2008
-
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials..
155:298-302.
2008
-
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality..
155:87-93.
2008
-
Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression..
155:56-61.
2008
-
Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report..
155:140-146.
2008
-
Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial..
155:121-127.
2008
-
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial..
155:33-41.
2008
-
Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study..
155:147-153.
2008
-
The pathophysiology of acute heart failure--is it all about fluid accumulation?.
155:9-18.
2008
-
A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative..
154:1206-1220.
2007
-
The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS)..
154:1086-1094.
2007
-
Dietary carbohydrate intake and high-sensitivity C-reactive protein in at-risk women and men..
154:962-968.
2007
-
Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation..
154:893-898.
2007
-
Training cardiovascular specialists in imaging: a curriculum based on fundamental concepts required for multimodal imaging..
154:838-845.
2007
-
Benefits of coronary revascularization: a failure to communicate..
154:613-614.
2007
-
Genetic association studies; the good, the bad, and the ugly..
154:610-612.
2007
-
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial..
154:702-709.
2007
-
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome..
154:624-631.
2007
-
Mobile cardiac catheterization laboratories increase use of cardiac care in women and African Americans..
154:532-538.
2007
-
The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan..
154:461-469.
2007
-
Highlights from the 56th annual scientific sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia..
154:247-259.
2007
-
Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction..
154:379-384.
2007
-
Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)..
154:277.e1-277.e8.
2007
-
No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial..
154:306-312.
2007
-
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials..
154:313-321.
2007
-
Effect of exercise training on ventricular function, dyssynchrony, resting myocardial perfusion, and clinical outcomes in patients with heart failure: a nuclear ancillary study of Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION); design and rationale..
154:46-53.
2007
-
Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry..
154:12-38.
2007
-
Relationship between depressive symptoms and long-term mortality in patients with heart failure..
154:102-108.
2007
-
Hypertension Intervention Nurse Telemedicine Study (HINTS): testing a multifactorial tailored behavioral/educational and a medication management intervention for blood pressure control..
153:918-924.
2007
-
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)..
153:960-969.
2007
-
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death..
153:941-950.
2007
-
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy..
153:951-959.
2007
-
Prognostic role of transesophageal echocardiography in acute type A aortic dissection..
153:1013-1020.
2007
-
Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)..
153:1089-1094.
2007
-
Absence of bilateral vision loss from amiodarone: a randomized trial..
153:837-842.
2007
-
Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting..
153:732-742.
2007
-
The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents..
153:743-748.
2007
-
Diagnostic monitoring strategies in heart failure management..
153:12-17.
2007
-
Diastolic heart failure and continuous hemodynamic monitoring..
153:6-11.
2007
-
Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction..
153:507-514.
2007
-
Revascularization for heart failure..
153:65-73.
2007
-
Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome..
153:53-58.
2007
-
Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)..
153:573-578.
2007
-
The new heart failure guidelines: strategies for implementation..
153:2-5.
2007
-
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification..
153:493-499.
2007
-
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale..
153:201-211.
2007
-
Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study..
153:245-252.
2007
-
Noninvasive imaging for coronary artery disease: a technology assessment for the Medicare Coverage Advisory Commission..
153:161-174.
2007
-
Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)..
153:82.e1-82.11.
2007
-
Complementarity and competitiveness of the intrinsic and extrinsic components of the total ventricular load: demonstration after valve replacement in aortic stenosis..
153:4-6.
2007
-
Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure..
153:98-104.
2007
-
Ventricular ectopy: impact of self-reported stress after myocardial infarction..
153:133-139.
2007
-
Continued improvements in quality improvement research..
152:1005-1006.
2006
-
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial..
152:1042-1050.
2006
-
Evaluation of dyslipidemia in the emergency department: impact of cholesterol testing on subsequent therapy..
152:1182-1186.
2006
-
Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center..
152:1007-1014.
2006
-
Trends in postoperative length of stay after bypass surgery..
152:1194-1200.
2006
-
Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design..
152:851.e1-851.11.
2006
-
Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure..
152:974.e7-974.11.
2006
-
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS..
152:684.e1-684.e9.
2006
-
Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts..
152:801-806.
2006
-
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative..
152:641-647.
2006
-
Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks..
152:661-667.
2006
-
Response of high-sensitivity C-reactive protein to exercise training in an at-risk population..
152:793-800.
2006
-
The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes..
152:648-660.
2006
-
Contemporary performance of surgical ventricular restoration procedures: data from the Society of Thoracic Surgeons' National Cardiac Database..
152:494-499.
2006
-
Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma..
152:478-485.
2006
-
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial..
152:500-508.
2006
-
Improved outcomes in peripartum cardiomyopathy with contemporary..
152:509-513.
2006
-
National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance..
152:454.e1-454.e8.
2006
-
Reflections on early stopping of a clinical trial..
152:407-409.
2006
-
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview..
152:291-296.
2006
-
Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease..
152:298-304.
2006
-
Predicting significant coronary artery disease in patients with left ventricular dysfunction..
152:340-347.
2006
-
Racial differences are seen in blood pressure response to fosinopril in hypertensive children..
152:394-399.
2006
-
The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience..
152:277-284.
2006
-
Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE)..
152:110-117.
2006
-
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both..
152:183-189.
2006
-
Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study..
152:126-135.
2006
-
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program..
152:86-92.
2006
-
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative..
152:140-148.
2006
-
Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial..
151:1180-1185.
2006
-
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial..
151:1231-1238.
2006
-
Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction..
151:1288-1295.
2006
-
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes..
151:1205-1213.
2006
-
Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm..
151:1043-1049.
2006
-
Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)..
151:1123-1128.
2006
-
How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study..
151:999-1005.
2006
-
Multifaceted intervention to promote beta-blocker use in heart failure..
151:992-998.
2006
-
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial..
151:985-991.
2006
-
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial..
151:985-991.
2006
-
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction..
151:787-790.
2006
-
From efficacy to safety concerns: a STEP forward or a step back for clinical research and intercessory prayer? The Study of Therapeutic Effects of Intercessory Prayer (STEP)..
151:762-764.
2006
-
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design..
151:786.e1-786.10.
2006
-
Unraveling the pathophysiology of acute heart failure: an inflammatory proposal..
151:765-767.
2006
-
Clinical trial issues in weight-loss therapy..
151:633-642.
2006
-
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial..
151:689.e1-689.e10.
2006
-
Nutrition as a contributor and treatment option for overweight and obesity..
151:628-632.
2006
-
Obesity and physical activity: a review..
151:598-603.
2006
-
Pharmacological and surgical treatments for obesity..
151:604-624.
2006
-
The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST)..
151:699-705.
2006
-
The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE)..
151:654-660.
2006
-
What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction?.
151:668-673.
2006
-
A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research..
151:451-456.
2006
-
Anemia in patients with heart failure and preserved systolic function..
151:457-462.
2006
-
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction..
151:316-322.
2006
-
Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies..
151:360-366.
2006
-
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial..
151:373-379.
2006
-
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials..
151:16-24.
2006
-
Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction..
151:168-175.
2006
-
Long-term adherence with cardiovascular drug regimens..
151:185-191.
2006
-
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry..
151:206-212.
2006
-
Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials..
151:10-15.
2006
-
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial..
151:92-99.
2006
-
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials..
150:1260-1267.
2005
-
Antidepressant therapy in patients with ischemic heart disease..
150:871-881.
2005
-
Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial..
150:893-898.
2005
-
The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort..
150:1086-1091.
2005
-
Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database..
150:1092-1098.
2005
-
Design and methodology of the Occluded Artery Trial (OAT)..
150:627-642.
2005
-
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial..
150:659-665.
2005
-
Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?.
150:650-651.
2005
-
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics..
150:643-649.
2005
-
The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use..
150:725-728.
2005
-
Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes?.
150:617-619.
2005
-
Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients..
150:402-410.
2005
-
Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited..
150:358-364.
2005
-
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)..
150:323-329.
2005
-
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial..
150:189-192.
2005
-
Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide?.
150:1-3.
2005
-
Depression and ischemic heart disease: what have we learned so far and what must we do in the future?.
150:54-78.
2005
-
Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial..
150:116-122.
2005
-
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial..
150:79-88.
2005
-
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)..
150:46-53.
2005
-
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial..
150:89-93.
2005
-
Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative..
149:1043-1049.
2005
-
Genetic association studies in cardiology..
149:964-970.
2005
-
Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida..
149:1009-1019.
2005
-
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004..
149:1020-1034.
2005
-
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I..
149:971-976.
2005
-
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II..
149:977-983.
2005
-
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale..
149:994-1002.
2005
-
Depression and heart failure in patients with a new myocardial infarction..
149:851-855.
2005
-
Diet and blood pressure: applying the evidence to clinical practice..
149:804-812.
2005
-
Improvements in quality improvement..
149:751-752.
2005
-
Improving blood pressure control by tailored feedback to patients and clinicians..
149:795-803.
2005
-
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes..
149:S91-S99.
2005
-
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction..
149:637-644.
2005
-
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy..
149:670-674.
2005
-
Intensity and focus of heart failure disease management after hospital discharge..
149:715-721.
2005
-
Metaanalysis and review of heart failure disease management randomized controlled clinical trials..
149:722-729.
2005
-
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention..
149:402-407.
2005
-
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus..
149:434-443.
2005
-
Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes..
149:474-481.
2005
-
Reducing the costs of phase III cardiovascular clinical trials..
149:482-488.
2005
-
Statin therapy--time to turn the focus from efficacy to implementation?.
149:381-383.
2005
-
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy..
149:138-144.
2005
-
Metabolic syndrome: definition, pathophysiology, and mechanisms..
149:33-45.
2005
-
Metabolic syndrome: evaluation of pathological and therapeutic outcomes..
149:20-32.
2005
-
Novel constructs for thrombin inhibition..
149:S61-S72.
2005
-
Thrombin: science and application in clinical practice..
149:S1.
2005
-
Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician..
149:S2-S8.
2005
-
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes..
148:e27.
2004
-
Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome..
148:1020-1027.
2004
-
Hand-held echocardiographic examination of patients with symptoms of acute coronary syndromes in the emergency department: the 30-day outcome associated with normal left ventricular wall motion..
148:1096-1101.
2004
-
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale..
148:764-775.
2004
-
Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative..
148:S34-S39.
2004
-
Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy..
148:795-802.
2004
-
Success stories: how hospitals are improving care..
148:S52-S55.
2004
-
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome..
148:439-446.
2004
-
Multicenter experience in revascularization of very elderly patients..
148:486-492.
2004
-
Charting the course of clinical research: from an inspired past to a promising future..
148:190-192.
2004
-
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library..
148:269-276.
2004
-
Highlights from the American College of Cardiology Annual Scientific Sessions 2004: March 9-12, 2004..
148:254.
2004
-
Left ventricular assist devices as destination therapy for end-stage heart failure..
148:252-253.
2004
-
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT..
148:62-71.
2004
-
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)..
148:122-128.
2004
-
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design..
148:43-51.
2004
-
Racial differences in the outcomes of patients with diastolic heart failure..
148:151-156.
2004
-
Should we cross the valve: the risk of retrograde catheterization of the left ventricle in patients with aortic stenosis..
148:41-42.
2004
-
Adenosine stress cardiac magnetic resonance imaging..
147:991-992.
2004
-
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction..
147:993-998.
2004
-
Part I: Identifying holes in the safety net..
147:977-984.
2004
-
Part II: Sealing holes in the safety net..
147:985-990.
2004
-
Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy..
147:790-791.
2004
-
Angiotensin-converting enzyme inhibitors: a new therapy for atrial fibrillation?.
147:751-752.
2004
-
Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction..
147:847-852.
2004
-
Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS..
147:865-873.
2004
-
Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction..
147:905-909.
2004
-
Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction..
147:698-704.
2004
-
Differences in care-seeking behavior for acute chest pain in the United States and Japan..
147:630-635.
2004
-
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial..
147:E16.
2004
-
Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial..
147:669-675.
2004
-
Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999..
147:582-586.
2004
-
Mortality in primary and secondary myocarditis..
147:746-750.
2004
-
Novel approaches to clinical trials: device-related infections..
147:599-604.
2004
-
To transfer or not to transfer: acute myocardial infarction reperfusion..
147:573-574.
2004
-
Aborted infarction: the ultimate myocardial salvage..
147:390-394.
2004
-
Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches..
147:401-411.
2004
-
Economic impact of drug-eluting stents on hospital systems: a disease-state model..
147:449-456.
2004
-
Feasibility of point-of-care echocardiography by internal medicine house staff..
147:476-481.
2004
-
Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis..
147:546-552.
2004
-
Importance of aggressive evaluation in patients with Staphylococcus aureus bacteremia..
147:379-380.
2004
-
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials..
147:457-462.
2004
-
Radiation safety in the cardiac catheterization laboratory..
147:375-378.
2004
-
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy..
147:267-274.
2004
-
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes..
147:246-252.
2004
-
Clinical trials in Japan and the United States..
147:200-201.
2004
-
Five-year clinical and echocardiographic evaluation of the Das AngelWings atrial septal occluder..
147:361-368.
2004
-
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients..
147:331-338.
2004
-
Training trials in heart failure: time to exercise restraint?.
147:190-192.
2004
-
Which beta-blocker for heart failure?.
147:238.
2004
-
Access site for cardiac catheterization..
147:1-2.
2004
-
Exploring options for improving healthcare..
147:23-30.
2004
-
Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study..
147:151-157.
2004
-
Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass..
147:173-180.
2004
-
A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes..
146:993-998.
2003
-
Addition of right-sided and posterior precordial leads during stress testing..
146:1090-1094.
2003
-
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies..
146:948-957.
2003
-
C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy..
146:1099-1104.
2003
-
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies..
146:958-968.
2003
-
Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy..
146:944-945.
2003
-
Where the rubber meets the road in pharmacogenetics: assessment of gene-environment interactions..
146:929-931.
2003
-
"Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction..
146:757-763.
2003
-
Death in patients with permanent pacemakers for sick sinus syndrome..
146:887-893.
2003
-
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS)..
146:862-869.
2003
-
Evaluation of the dofetilide risk-management program..
146:894-901.
2003
-
Assessing risk for coronary heart disease: beyond Framingham..
146:572-580.
2003
-
Changing the model of care for patients with acute coronary syndromes..
146:605-612.
2003
-
Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy..
146:640-645.
2003
-
Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial..
146:713-720.
2003
-
Platelet activation after stenting with heparin-coated versus noncoated stents..
146:E10.
2003
-
Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis..
146:621-627.
2003
-
Screening for structural heart disease: time to stop listening and start looking..
146:570-571.
2003
-
Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II)..
146:484-488.
2003
-
Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave?.
146:383-384.
2003
-
Heart failure and the elderly: disease diversity, data, and delivery of care..
146:194-196.
2003
-
Vegetations in endocarditis: big is bad, but is there more to it?.
146:189-190.
2003
-
Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction..
146:48-54.
2003
-
Depression and increased myocardial ischemic activity in patients with ischemic heart disease..
146:55-61.
2003
-
Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy)..
146:91-98.
2003
-
Highlights from the American College of Cardiology Annual Scientific Sessions 2003: March 28 to April 2, 2003..
146:19-26.
2003
-
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction..
146:27-32.
2003
-
Vasopressin: a new target for the treatment of heart failure..
146:9-18.
2003
-
Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery..
145:1108-1113.
2003
-
Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction..
145:1051-1057.
2003
-
Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry..
145:868-874.
2003
-
Differential effects of exercise training in men and women with chronic heart failure..
145:912-918.
2003
-
Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?.
145:758-767.
2003
-
To the editor..
145:e26.
2003
-
Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study..
145:602-613.
2003
-
Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy..
145:636-642.
2003
-
Effect of cardiac rehabilitation on functional outcomes after coronary revascularization..
145:445-451.
2003
-
Highlights from the American Heart Association annual scientific sessions 2002: November 17 to 20, 2002..
145:554-562.
2003
-
Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?.
145:397-403.
2003
-
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial..
145:515-521.
2003
-
A bridge for the 21st century in heart transplantation?.
145:198-199.
2003
-
Angiographic changes in vein grafts: stable surrogate or seductive siren?.
145:187-189.
2003
-
Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial..
145:S62-S66.
2003
-
Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure..
145:S47-S50.
2003
-
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada..
145:349-355.
2003
-
Is specialty care associated with improved survival of patients with congestive heart failure?.
145:300-309.
2003
-
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial..
145:239-247.
2003
-
Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study..
145:S60-S61.
2003
-
Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF)..
145:S55-S57.
2003
-
Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure..
145:S51-S54.
2003
-
Surrogate end points in heart failure trials..
145:S67-S70.
2003
-
Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4)..
145:S58-S59.
2003
-
The finer points of race and hypertension..
145:206-208.
2003
-
The problem of decompensated heart failure: nomenclature, classification, and risk stratification..
145:S18-S25.
2003
-
Double negatives..
145:9-11.
2003
-
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials..
145:73-79.
2003
-
Hierarchical modeling: its time has come..
145:16-18.
2003
-
Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction..
145:118-124.
2003
-
Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America..
145:1-8.
2003
-
Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials..
145:47-57.
2003
-
Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial..
145:179-186.
2003
-
Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations..
144:957-980.
2002
-
Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes..
144:987-994.
2002
-
Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies..
144:1065-1073.
2002
-
Genetics in heart failure: practical incorporation of this new biologic dimension..
144:938-940.
2002
-
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)..
144:995-1002.
2002
-
Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape..
144:747-749.
2002
-
Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management..
144:769-781.
2002
-
Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients..
144:750-752.
2002
-
Oral antihypertensive trial design and analysis under the pediatric exclusivity provision..
144:608-614.
2002
-
Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4)..
144:583-588.
2002
-
Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator..
144:440-448.
2002
-
Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications..
144:501-507.
2002
-
Reperfusion in waiting: what queue should we join?.
144:377-379.
2002
-
Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated?.
144:373-376.
2002
-
Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era..
144:243-250.
2002
-
Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women..
144:297-302.
2002
-
Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100..
144:151-158.
2002
-
Diuretic resistance predicts mortality in patients with advanced heart failure..
144:31-38.
2002
-
Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries..
144:73-80.
2002
-
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries..
144:81-88.
2002
-
The state of exercise training: a need for action..
144:1-4.
2002
-
Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?.
143:1068-1075.
2002
-
Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure..
143:1112-1117.
2002
-
Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy..
143:894-903.
2002
-
Is more better?.
143:745-747.
2002
-
Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease..
143:711-717.
2002
-
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists..
143:594-601.
2002
-
Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction..
143:460-466.
2002
-
Should reperfusion strategies in myocardial infarction be modified for the very elderly?.
143:373-376.
2002
-
Adhesion molecules, platelet activation, and cardiovascular risk..
143:196-198.
2002
-
Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001..
143:217-228.
2002
-
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial..
143:242-248.
2002
-
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment..
143:205-216.
2002
-
Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial..
143:95-105.
2002
-
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy..
143:106-110.
2002
-
Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts..
143:111-117.
2002
-
Variability in cost of coronary bypass surgery in New York State: potential for cost savings..
143:130-139.
2002
-
Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure..
142:932-933.
2001
-
Results of Expert Meetings: Obesity and Cardiovascular Disease. Introduction: Cardiologists should target obesity..
142:1088-1090.
2001
-
Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity as a risk factor in coronary artery disease..
142:1102-1107.
2001
-
Advanced coronary artery disease: Appropriate end points for trials of novel therapies..
142:843-851.
2001
-
Cardiac rehabilitation in the elderly..
142:748-755.
2001
-
Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes: Monitoring and Actualization of Noetic Training (MANTRA) feasibility pilot..
142:760-769.
2001
-
Uniform platelet activation exists before coronary stent implantation despite aspirin therapy..
142:611-616.
2001
-
Genetic analysis for common complex disease..
140:S36-S44.
2000
-
Genetic approaches for the investigation of genes associated with coronary heart disease..
140:S27-S35.
2000
-
Genetics of coronary heart disease: current knowledge and research principles..
140:S11-S26.
2000
-
Genetics of coronary heart disease: current understanding and future prospects..
140:S1-S2.
2000
-
Recommendations for national and local regulatory authorities concerning research in genetic markers of disease..
140:S3-S5.
2000
-
The mode selection trial (MOST) in sinus node dysfunction: design, rationale, and baseline characteristics of the first 1000 patients..
140:541-551.
2000
-
Novel oral anticoagulants and reversal agents: Considerations for clinical development..
169:751-757.
2015
-
Electronic health record characterization and outcomes of heart failure with preserved ejection fraction.
2023
-
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial.
2022
-
Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial.
2018
-
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
2017
-
Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes.
2017
-
Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
2015
-
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
2014
-
Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States.
2013